Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Veradermics, Incorporated Common Stock
(NY:
MANE
)
101.21
-3.79 (-3.61%)
Streaming Delayed Price
Updated: 11:50 AM EDT, Aug 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Veradermics, Incorporated Common Stock
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy
July 17, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics’ Oral VDPHL01 Delivers Positive Study ‘207’ Phase 2 Clinical Trial Results in Female Pattern Hair Loss Ahead of Upcoming Phase 2/3 Study ‘306’ Readout
July 15, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
July 14, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics to Present at Upcoming June Investor Conferences
May 28, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics Announces Poster Presentation on Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 at the 2026 World Congress for Hair Research
May 27, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
May 14, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
May 12, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
April 29, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics Announces Launch of Public Offering
April 27, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss
April 27, 2026
From
Veradermics, Inc.
Via
Business Wire
Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302’ Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss
April 26, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates
March 30, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics Announces Presentations on VDPHL01 and Patient Experiences With Pattern Hair Loss at 2026 American Academy of Dermatology Annual Meeting
March 18, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics to Participate in Upcoming March Investor Conferences
March 03, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss
February 09, 2026
From
Veradermics, Incorporated
Via
Business Wire
Veradermics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
February 05, 2026
From
Veradermics, Incorporated
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
